|
Real-time
Euronext Bruxelles
02:09:13 24/08/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 221.40 EUR | -0.14% |
|
+2.79% | -7.21% |
| 20/08 | Cancer vaccines finally garner the spotlight |  |
| 19/08 | Danish Pharma H. Lundbeck Expects No Slowdown for Primary Growth Driver Brands | MT |
Company Valuation: UCB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,947 | 13,973 | 14,969 | 36,464 | 45,333 | 42,270 | - | - |
| Change | - | -26.25% | 7.12% | 143.6% | 24.32% | -6.76% | - | - |
| Enterprise Value (EV) 1 | 19,807 | 15,973 | 17,146 | 37,918 | 45,326 | 42,591 | 40,471 | 37,889 |
| Change | - | -19.36% | 7.34% | 121.15% | 19.54% | -6.03% | -4.98% | -6.38% |
| P/E | 17.9x | 33.4x | 44.8x | 34.3x | 29.1x | 22.2x | 18.3x | 15x |
| PBR | 2.32x | 1.58x | 1.67x | 3.64x | 4.18x | 3.51x | 3.06x | 2.53x |
| PEG | - | -0.6x | -2.2x | 0x | 0.6x | 1x | 0.8x | 0.7x |
| Capitalization / Revenue | 3.28x | 2.53x | 2.85x | 5.93x | 5.86x | 4.87x | 4.36x | 3.92x |
| EV / Revenue | 3.43x | 2.9x | 3.26x | 6.16x | 5.86x | 4.9x | 4.18x | 3.51x |
| EV / EBITDA | 12.1x | 12.7x | 12.7x | 25.7x | 17.2x | 14x | 11.1x | 8.83x |
| EV / EBIT | 15x | 23.7x | 26.1x | 45.4x | 22.6x | 17.4x | 13.5x | 10.3x |
| EV / FCF | 15.6x | 18.4x | 38.5x | 41.2x | 24.6x | 22.3x | 15.3x | 12.2x |
| FCF Yield | 6.42% | 5.43% | 2.6% | 2.43% | 4.06% | 4.48% | 6.53% | 8.23% |
| Dividend per Share 2 | 1.3 | 1.33 | 1.36 | 1.39 | 1.45 | 1.457 | 1.502 | 1.534 |
| Rate of return | 1.3% | 1.81% | 1.72% | 0.72% | 0.61% | 0.66% | 0.68% | 0.69% |
| EPS 2 | 5.6 | 2.2 | 1.76 | 5.61 | 8.2 | 9.986 | 12.14 | 14.79 |
| Distribution rate | 23.2% | 60.5% | 77.3% | 24.8% | 17.7% | 14.6% | 12.4% | 10.4% |
| Net sales 1 | 5,777 | 5,517 | 5,252 | 6,152 | 7,741 | 8,688 | 9,690 | 10,785 |
| EBITDA 1 | 1,641 | 1,260 | 1,349 | 1,476 | 2,636 | 3,038 | 3,648 | 4,291 |
| EBIT 1 | 1,318 | 675 | 657 | 836 | 2,009 | 2,444 | 3,001 | 3,675 |
| Net income 1 | 1,058 | 418 | 343 | 1,065 | 1,558 | 1,925 | 2,327 | 2,827 |
| Net Debt 1 | 860 | 2,000 | 2,177 | 1,454 | -7 | 321.2 | -1,799 | -4,381 |
| Reference price 2 | 100.35 | 73.56 | 78.90 | 192.20 | 238.60 | 221.70 | 221.70 | 221.70 |
| Nbr of stocks (in thousands) | 1,88,812 | 1,89,959 | 1,89,721 | 1,89,720 | 1,89,996 | 1,90,663 | - | - |
| Announcement Date | 24/02/22 | 22/02/23 | 28/02/24 | 27/02/25 | 24/02/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22.2x | 4.9x | 14.02x | 0.66% | 4.93TCr | |
| 19.31x | 4.52x | 10.64x | 0.47% | 8.33TCr | |
| -16.91x | 25.77x | -16.64x | -.--% | 5.79TCr | |
| 19.86x | 4.25x | 13.12x | 2.5% | 5.78TCr | |
| 37.73x | 12.91x | 24.53x | -.--% | 5.17TCr | |
| 38.52x | 3.54x | 13.49x | -.--% | 3.2TCr | |
| 57.04x | 3.65x | 28.27x | -.--% | 2.59TCr | |
| 75.75x | 7.38x | 49.38x | -.--% | 2.27TCr | |
| 24.11x | 5.18x | 13.48x | -.--% | 1.69TCr | |
| 75.15x | 45.28x | 65.75x | 0.15% | 1.61TCr | |
| Average | 35.28x | 11.74x | 21.60x | 0.38% | 4.14TCr | |
| Weighted average by Cap. | 26.28x | 10.19x | 15.02x | 0.53% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- UCB Stock
- Valuation UCB
Select your edition
All financial news and data tailored to specific country editions
